Physicians' Academy for Cardiovascular Education

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College Londen, UK - Online CME

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Management of CV Risk & T2DM: Implications of novel outcome trials

10' education - Aug. 28, 2017 - Barcelona, Spain - John E Deanfield, MD, London, UK - PACE-CME symposium held at ESC 2017

SGLT2 inhibition in cardiology: What a cardiologist needs to know

10' education - Aug. 28, 2017 - Barcelona, Spain - Naveed Sattar, MD, Oxford, United Kingdom - PACE-CME symposium held at ESC 2017

How incretin therapy changes diabetes and prediabetes management

3' education - May 22, 2017

New diabetes drugs and heart failure: What have we learnt?

10' education - May 6, 2017 - Paris, France - John McMurray, MD - ESC Heart Failure, Paris

Modifying CV risk by managing diabetes

3' education - Nov. 12, 2016 - New Orleans, LA, USA - Jorge Plutzky, MD (Boston, MA, USA)
##SCROLLER_ITEMS_FULL_TITLE##

What do novel diabetes drugs add to CV risk reduction?

3' education - Oct. 19, 2014 - Snapshot 2014 - Dr Naveed Sattar
##SCROLLER_ITEMS_FULL_TITLE##

Effects of GLP-1 Analogs on Cardiovascular Health

3' education - Jan. 10, 2013 - LA, AHA 2012 - Dr. Richard Shannon

Glucagon-like peptide-1 analogue promotes weight loss in obese, non-diabetic individuals

Literature - Sep. 12, 2018 - O’Neil PM et al. - The Lancet 2018
In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.

In obese individuals without diabetes, semaglutide significantly and dose-dependently reduced body weight compared with placebo and liraglutide, on top of healthy diet and exercise.

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK
Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Multiple pathways play a role in the development of T2DM. This is why targeting multiple processes may improve glucose regulation. Prof. Bailey gives an extensive overview of the available therapeutic options, discussing mechanisms, advantages and disadvantages.

Meeting Impression | Contemporary management of a patient with heart failure and diabetes: Implications from recent trials

May 28, 2018 – Vienna, Austria
May 28, 2018 – Vienna, Austria

Download the meeting impression of this PACE symposium during Heart Failure 2018, which considered what recent outcome trials with glucose-lowering trials can tell us about us about optimal management of patients with HF and diabetes.

Summary | Guidance from outcome trials: What are the clinical implications

Vienna, Austria - May 28, 2018

Prof. Zannad compared the clinical outcomes in trials of various novel classes of glucose-lowering drugs, to postulate what these findings may tell us about their mechanism of action, and how they can be benefitted from in the management of patients with HF and diabetes.

Meeting Impression | Preventing CVD in Patients with T2DM

May 3, 2018 - Ljubljana, Slovenia
May 3, 2018 - Ljubljana, Slovenia

Download the meeting impression of this PACE symposium during EuroPrevent 2018, that considered how to apply novel outcome data with GLP-1 RA to clinical practice.

Summary | Practical management of cardiovascular risk: Lessons from latest diabetes trials

May 3, 2018 – Prof. Lars Rydén, MD

This is a summary of the presentation by prof. Rydén, in which he reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Summary | The cardiovascular challenge for primary care in diabetes

May 3, 2018 – Prof. Richard Hobbs, MD

This summary of the presentation by prof. Hobbs illustrates why diabetes poses a high burden to primary health care, since patients with T2DM are at high CV risk. This risk can be lowered by targeting various risk factors.

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK
Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Until recently, ESC Guidelines said little about management of patients with HF and T2DM. New treatment options have now become available. Prof. Cowie considers how cardiologists can be involved in T2DM care in their patients.

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France
Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Prof. Zannad carefully considers the trial results of novel antidiabetic drugs and speculates how they may have yielded their clinical effects, and which patients may benefit from them.

Oral GLP-1 receptor agonist reduces HbA1c and body weight in T2DM patients

News - July 12, 2018

In the PIONEER 1 and 3 phase 3a trials, oral semaglutide reduced HbA1c and body weight in T2DM patients compared to placebo or sitagliptin.

Dual GLP-1 and glucagon receptor agonist improves glycemic control and reduces body weight

Literature - July 4, 2018 - Ambery P et al. - Lancet 2018
In a phase 2a study, the dual GLP-1 and glucagon receptor agonist MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

In a phase 2a study, MEDI0382 improved glycemic control and reduced body weight in patients with stable type 2 diabetes who were overweight or obese.

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden
Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

Prof. Rydén reviews cardiovascular outcome trials with different types of GLP-1 RAs and explains the differences.

GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD